Imaging and diagnostic assessments for tauopathies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This protocol aims to gather critical data to evaluate the specificity of newly developed radiotracers through a multi-site diagnostic assessment core. It involves PET imaging of A-beta amyloid in individuals with Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Frontotemporal Dementia, and healthy controls. The study is a multicenter initiative led by the University of Pennsylvania, collaborating with several prestigious institutions. Participants will undergo brain MRI scans and neurologic exams as part of the assessment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants: Patients in all cohorts will range from 40 to 85 yrs and will be both male and female.
* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Participants who are deemed unable to provide informed consent must have a designated Legally Authorized Representative(LAR) present for consent and a Study Partner to accompany them to study visits. The LAR and the Study Partner may be the same person.
* Clinical diagnoses for each cohort will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP, FTD or Healthy control)

Exclusion Criteria:

* Females who are pregnant or breast feeding at the time of screening will be excluded
* Forms of parkinsonism other than PD, PSP and MSA as defined above
* Major psychiatric disorder (e.g. schizophrenia or bipolar disorder)
* History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported
* Contraindications or Inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician
* Implanted medical device or other contraindication to MRI
* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study
* Refusal to consent to brain donation (except for HC cohort). All non-HC participants must agree to postmortem brain donation..

Where it's running

• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Erin o Schubert
• Email: erin.schubert@pennmedicine.upenn.edu
• Phone: 2155736569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Brain PET scan with [18F]NIDF to see tau protein in Alzheimer’s and other tau-related diseases

  We are testing whether a new PET tracer called [18F]NIDF can safely show tau protein in the brains of healthy adults and people with Alzheimer’s disease or other tauopathies.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07306598

• ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease

  This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.

  Recruiting at 4 sites Phase 1/2 Arrowhead Pharmaceuticals · East York, Ontario and 3 other locations · NCT07221344

• Investigating a new radiotracer for brain tau protein in neurodegenerative diseases

  This study is testing a new imaging tool to see how well it can detect a specific brain protein linked to various neurodegenerative diseases in people who have these conditions and healthy individuals.

  Recruiting at 2 sites Early Phase 1 University of Pennsylvania · San Francisco, California and 1 other locations · NCT06932809

• Evaluating Tau PET/CT for Diagnosing Tau-Related Diseases

  This study is testing a new type of imaging scan to see if it can help doctors better diagnose Tau-related diseases in adults with suspected or diagnosed tumors.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690983

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.